Clinical Study of High Dose Calcium to Prevent Pregnancy Specific Hypertensive Disorders, Their Severity, Still A Research Agenda!

Open Journal of Gynaecology and Obstetrics Research Pub Date : 2022-01-20 DOI:10.36811/ojgor.2022.110019

Shakuntala Chhabra, akanksha Suman

{"title":"Clinical Study of High Dose Calcium to Prevent Pregnancy Specific Hypertensive Disorders, Their Severity, Still A Research Agenda!","authors":"Shakuntala Chhabra, akanksha Suman","doi":"10.36811/ojgor.2022.110019","DOIUrl":null,"url":null,"abstract":"Background: Worldwide hypertensive disorders of pregnancy (HDsP) continue to be leading causes of maternal, perinatal severe morbidity mortality, long term disabilities. Prevention of HDsP, their severity through high dose calcium supplementation is being suggested. However, whether calcium really helps is still not established. So, research continues.\n\nObjectives: Present study was carried out to know the efficacy of high dose daily calcium from midpregnancy on reduction in occurrence of HDsP, their severity and perinatal outcome.\n\nMaterial Methodology: Study was done with 1200 women, (600 cases, 600 controls) of 18-39 years with, 20 + 2 weeks pregnancy, no obvious medical disorders in mothers, no ultra sonographically diagnosed anomaly in fetus at entry to study. Study cases (S) received 2 gms oral calcium daily, similar controls (C) were not given calcium. Research assistant was not part of the care providers, but kept track of everything. Women got antenatal care, clinicians not knowing which women got extra calcium. Desired information, pregnancy outcome, complications during pregnancy, birth weight, neonatal outcome, admission of baby to neonatal intensive care unit and compliance to calcium tablets in study subjects was collected by research assistant using pretested tool.\n\nResults: HDsP occurred in 7.5% S cases, 7.33% C group. Amongst group S9.43% Primigravida, 4.3% Multigravida developed HDsP (gestational hypertension 6%, preeclampsia 1.16%, eclampsia 0.33%). In group C 8.04% primigravida, 3.08% multigravida developed HDsP, (6%GH, 1% preeclampsia, 0.33% eclampsia), Total 8.8% perinatal deaths occurred in S cases who had HDsP, 2.27% in C, with HDsP and no maternal death.\n\nConclusion: No benefit was found with high dose calcium. On the contrary, perinatal outcome was poorer. More research is needed about high dose calcium for HDsP, their severity, perinatal outcome.\n\nKeywords: Hypertensive Disorders of Pregnancy; Occurrence; Severity; Perinantal outcome","PeriodicalId":321045,"journal":{"name":"Open Journal of Gynaecology and Obstetrics Research","volume":"138 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Journal of Gynaecology and Obstetrics Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36811/ojgor.2022.110019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Worldwide hypertensive disorders of pregnancy (HDsP) continue to be leading causes of maternal, perinatal severe morbidity mortality, long term disabilities. Prevention of HDsP, their severity through high dose calcium supplementation is being suggested. However, whether calcium really helps is still not established. So, research continues. Objectives: Present study was carried out to know the efficacy of high dose daily calcium from midpregnancy on reduction in occurrence of HDsP, their severity and perinatal outcome. Material Methodology: Study was done with 1200 women, (600 cases, 600 controls) of 18-39 years with, 20 + 2 weeks pregnancy, no obvious medical disorders in mothers, no ultra sonographically diagnosed anomaly in fetus at entry to study. Study cases (S) received 2 gms oral calcium daily, similar controls (C) were not given calcium. Research assistant was not part of the care providers, but kept track of everything. Women got antenatal care, clinicians not knowing which women got extra calcium. Desired information, pregnancy outcome, complications during pregnancy, birth weight, neonatal outcome, admission of baby to neonatal intensive care unit and compliance to calcium tablets in study subjects was collected by research assistant using pretested tool. Results: HDsP occurred in 7.5% S cases, 7.33% C group. Amongst group S9.43% Primigravida, 4.3% Multigravida developed HDsP (gestational hypertension 6%, preeclampsia 1.16%, eclampsia 0.33%). In group C 8.04% primigravida, 3.08% multigravida developed HDsP, (6%GH, 1% preeclampsia, 0.33% eclampsia), Total 8.8% perinatal deaths occurred in S cases who had HDsP, 2.27% in C, with HDsP and no maternal death. Conclusion: No benefit was found with high dose calcium. On the contrary, perinatal outcome was poorer. More research is needed about high dose calcium for HDsP, their severity, perinatal outcome. Keywords: Hypertensive Disorders of Pregnancy; Occurrence; Severity; Perinantal outcome

查看原文本刊更多论文

高剂量钙预防妊娠高血压疾病的临床研究，其严重程度，仍是一个研究议程!

背景:在世界范围内，妊娠高血压疾病(HDsP)仍然是孕产妇、围产期严重发病率、死亡率和长期残疾的主要原因。建议通过高剂量补钙预防HDsP及其严重程度。然而，钙是否真的有帮助还没有确定。因此，研究仍在继续。目的:了解妊娠中期每日高剂量钙对降低HDsP发生、严重程度及围产儿结局的影响。材料方法学:研究对象为年龄在18-39岁、妊娠20 + 2周、母体无明显内科疾病、入组时胎儿无超声诊断异常的女性1200名(600例，600例对照)。研究病例(S)每天口服2克钙，相似的对照组(C)不给予钙。研究助理不是护理人员的一部分，但会记录一切。妇女得到了产前护理，临床医生不知道哪些妇女得到了额外的钙。研究助理使用预测工具收集研究对象的期望信息、妊娠结局、妊娠并发症、出生体重、新生儿结局、婴儿入住新生儿重症监护病房和钙片依从性。结果:S组HDsP发生率为7.5%，C组为7.33%。其中原产组为9.43%，多胎组为4.3%(妊娠高血压6%，先兆子痫1.16%，子痫0.33%)。C组初产妇8.04%，多胎产妇3.08%发生HDsP， (gh 6%，先兆子痫1%，子痫0.33%)，5例HDsP围产儿总死亡率8.8%，C组2.27%，伴HDsP，无产妇死亡。结论:大剂量补钙无明显疗效。相反，围产期结果较差。高剂量钙治疗HDsP，其严重程度，围产期结局需要更多的研究。关键词:妊娠期高血压疾病;发生;严重程度;Perinantal结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Journal of Gynaecology and Obstetrics Research

自引率

0.00%

发文量